Paclitaxel is widely used in the combination chemotherapy for many cancers including esophageal squamous cell carcinoma (ESCC). However, the paclitaxel resistance occurs frequently in treating ESCC and the mechanism is not fully understood yet. The heterogeneity of gene expression within the drug-resistant cancer cells may be one of the major factors contributing to its resistance. In the present study, we successfully induced paclitaxel resistance in ESCC cell line KYSE-30 through low dose and long-term treatment of paclitaxel.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2DY27RH
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Objectives Patients undergoing osteoporosis treatment benefit greatly from early detection. We previously developed a computer-...
-
Publication date: Available online 20 March 2018 Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology Author(s): Tobia...
-
Cerebral Microbleeds: Imaging and Clinical Significance. Radiology. 2018 Apr;287(1):11-28 Authors: Haller S, Vernooij MW, Kuij...
-
IJMS, Vol. 19, Pages 177: Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy International Journal of Molecular Sciences doi: 10.3390/...
-
Related Articles Physician Dismissal of Families Who Refuse Vaccination: An Ethical Assessment. J Law Med Ethics. 2015;43(3):654-60 ...
-
Chicago's other mag mile: The second-highest-grossing shopping district in the city is a two-mile stretch of 26th Street on the Southwes...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου